<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">29</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0387</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>SERPING1</italic> polymorphisms in polypoidal choroidal vasculopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Meng</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wen</surname><given-names>Feng</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zuo</surname><given-names>Chengguo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiongze</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hui</given-names></name></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Shizhou</given-names></name></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Guangwei</given-names></name></contrib><aff id="aff1">State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Feng Wen, M.D., Ph.D., State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 South Xianlie Road, Guangzhou, 510060, China; Phone: +86 20 87330292; FAX: +86 20 87333271; email: <email xlink:href="wenfeng208@yahoo.com.cn">wenfeng208@yahoo.com.cn</email></corresp></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>16</day><month>2</month><year>2010</year></pub-date><volume>16</volume><fpage>231</fpage><lpage>239</lpage><history><date date-type="received"><day>09</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>09</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Molecular Vision.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To investigate whether common genetic variants in the complement component 1 inhibitor gene (serpin peptidase inhibitor, clade G, member 1, <italic>SERPING1</italic>) are associated with polypoidal choroidal vasculopathy (PCV) in a Chinese Han population.</p></sec><sec><title>Methods</title><p>DNA samples were obtained from 118 PCV patients and 115 healthy subjects. Data derived from the HapMap project were used to select tag single nucleotide polymorphisms (SNPs) across the extended <italic>SERPING1</italic> region. A previously reported age-related macular degeneration-related risk factor (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link>) was forcibly included. Genotyping of each tag SNP was performed by PCR restriction fragment length polymorphism and direct DNA sequencing techniques.</p></sec><sec><title>Results</title><p>Four SNPs for <italic>SERPING1</italic>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link>, were chosen as tag SNPs. None of these tag SNPs were associated with PCV, according to the single-SNP association test (p=0.41&#x02013;0.83). Evaluation of common haplotypes across <italic>SERPING1</italic> did not reveal any association with PCV (p=0.49&#x02013;0.82).</p></sec><sec><title>Conclusions</title><p>We found no evidence to support the role of any common <italic>SERPING1</italic> variants, including the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link> variant, in the susceptibility to PCV in a Chinese Han population.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Wen</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Polypoidal choroidal vasculopathy (PCV) is a hemorrhagic and exudative macular disease that shows distinct forms of choroidal vascular abnormalities, including abnormal choroidal vascular networks and polypoidal lesions at their borders [<xref ref-type="bibr" rid="r1">1</xref>-<xref ref-type="bibr" rid="r3">3</xref>]. PCV has a particularly high incidence among the exudative age-related macular degeneration (AMD) in Asian populations, accounting for 24.5% of exudative AMD in the Chinese population [<xref ref-type="bibr" rid="r4">4</xref>] and 54.7% in the Japanese population [<xref ref-type="bibr" rid="r5">5</xref>] compared with only 8%&#x02013;13% in Caucasians [<xref ref-type="bibr" rid="r3">3</xref>].</p><p>PCV shares many similarities with neovascular AMD, including demography [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r5">5</xref>], pathology [<xref ref-type="bibr" rid="r6">6</xref>-<xref ref-type="bibr" rid="r8">8</xref>], and manifestation [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r5">5</xref>]. Due to the similarities between PCV and neovascular AMD, most genetic risk factors for PCV were found based on previous genetic studies for AMD patients. Several genetic risk factors for AMD have been established, including the complement factor H (<italic>CFH</italic>) gene on chromosome 1q32 [<xref ref-type="bibr" rid="r9">9</xref>-<xref ref-type="bibr" rid="r13">13</xref>] and two tightly linked genes, namely age-related maculopathy susceptibility 2 (<italic>ARMS2</italic>) and high-temperature requirement factor A1 (<italic>HTRA1</italic>) on chromosome 10q26 [<xref ref-type="bibr" rid="r14">14</xref>-<xref ref-type="bibr" rid="r16">16</xref>]. Several recent studies have shown a strong association between PCV and these variants [<xref ref-type="bibr" rid="r17">17</xref>-<xref ref-type="bibr" rid="r22">22</xref>].</p><p>Since the discovery of the association between AMD and variants in <italic>CFH</italic>, several other genes regulating or involved in the alternative pathway of complement activation have been found to show a strong association with AMD, including those coding for complement component 3 (<italic>C3</italic>) [<xref ref-type="bibr" rid="r23">23</xref>], complement factor B (<italic>CFB</italic>), and complement factor 2 (<italic>C2</italic>) [<xref ref-type="bibr" rid="r24">24</xref>]. The complement factor 1 (<italic>C1</italic>) inhibitor is encoded by the serpin peptidase inhibitor, clade G, member 1 <italic>(SERPING1)</italic> gene (GenBank <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=NM_000062">NM_000062</ext-link>) and is a member of a large family of serine proteases. The protein encoded by <italic>SERPING1</italic> is a key regulator of the classical pathway for complement activation. It has been reported to downregulate the alternative pathway in vitro by binding to <italic>C3b</italic> and inhibiting the binding of <italic>CFB</italic> to <italic>C3b</italic> [<xref ref-type="bibr" rid="r25">25</xref>]. Recently, Ennis et al. reported a protective effect on AMD for the minor allele of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link> within intron 6 of <italic>SERPING1</italic> [<xref ref-type="bibr" rid="r26">26</xref>]. However, the association was not replicated in another study conducted by Park et al. [<xref ref-type="bibr" rid="r27">27</xref>].</p><p>Considering the similarities between PCV and neovascular AMD and the strong association between PCV and <italic>CFH</italic>, we hypothesized that polymorphisms in the <italic>SERPING1</italic> gene, another regulator of the complement system, might play a role in the development of PCV. In this study, we genotyped four tag single nucleotide polymorphisms (SNPs) that are highly representative of the common genetic variations in the <italic>SERPING1</italic> region and analyzed the associations between these variants and PCV in a Chinese Han population.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study participants</title><p>The study protocol was approved by the institutional review board at the Zhongshan Ophthalmic Center of Sun Yat-sen University, Guangzhou, China, and performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects before participation in this study. All cases and controls included in this study were Chinese Han individuals recruited from the Zhongshan Ophthalmic Center.</p><p>All PCV patients underwent ophthalmic examinations, including visual acuity measurements, slit-lamp biomicroscopy, ophthalmoscope, color fundus photographs, fluorescein angiography, and indocyanine green angiography (ICGA). The diagnosis of PCV was based on identification of polypoidal choroidal vascular dilations with or without branching inner choroidal vessels on ICGA. Thus, all PCV patients enrolled in this study met the criteria of definitive cases of PCV, as proposed by the Japanese Study Group of Polypoidal Choroidal Vasculopathy [<xref ref-type="bibr" rid="r28">28</xref>]. Definitive cases of PCV must satisfy at least one of the following two criteria: (1) protruding orange-red lesions visible on fundus examination; (2) characteristic polypoidal lesions evident (<xref ref-type="fig" rid="f1">Figure 1</xref>) on ICGA. Patients with other neovascularized maculopathies, such as neovascular AMD, pathologic myopia, angioid streaks, presumed ocular histoplasmosis, and retinal angiomatous proliferation, were excluded. The characteristics of the study group are summarized in <xref ref-type="table" rid="t1">Table 1</xref>.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Clinical photos of polypoidal choroidal vasculopathy (PCV). <bold>A</bold>: Color fundus photograph of a patient with PCV. Several orange lesions are visible in the macula. Hemorrhage is visible between the orange lesions and the optic disk. <bold>B</bold>: The diagnosis of PCV was confirmed with indocyanine green angiography (ICGA). Abnormal choroidal vascular networks and characteristic polypoidal lesions are visible in the macula, corresponding to the orange lesion in the color fundus photograph.</p></caption><graphic xlink:href="mv-v16-231-f1"/></fig><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Characteristics of the study population</title></caption><table frame="hsides" rules="groups"><col width="140" span="1"/><col width="54" span="1"/><col width="63" span="1"/><col width="63" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">&#x000a0;<bold>Demographic characteristics</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCV</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Number of subjects<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">118<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">115<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gender (male/female)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78/40<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69/46<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.335<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mean age&#x000b1;SD (years)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65&#x000b1;8.4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69&#x000b1;8.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age range (years)</td><td valign="top" align="center" rowspan="1" colspan="1">43&#x02013;85</td><td valign="top" align="center" rowspan="1" colspan="1">50&#x02013;87</td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PCV represents Polypoidal Choroidal Vasculopathy; SD represents standard deviation.</p></table-wrap-foot></table-wrap><p>All control subjects underwent comprehensive ophthalmic examinations, and those with macular degeneration of any cause, macular changes (such as drusen or pigment abnormalities), or media opacities preventing clear visualization of the macula were excluded from the recruitment. All control subjects were unrelated to case subjects and were aged &#x02265;50 years.</p></sec><sec><title>Single nucleotide polymorphism selection</title><p>SNPs across <italic>SERPING1</italic>, including 5 kb upstream and downstream in the international haplotype map (HapMap) [<xref ref-type="bibr" rid="r29">29</xref>] for the Han Chinese in Beijing, China (CHB), were used to select tag SNPs. SNPs with a minor allele frequency above 5% were evaluated for linkage disequilibrium (LD) using <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview">Haploview software 4.1</ext-link> [<xref ref-type="bibr" rid="r30">30</xref>]. A minimum threshold value of 0.8 for the r<sup>2</sup> parameter was set in the Haploview software. r<sup>2</sup> represents the multivariate coefficient of determination for all alleles that are to be captured. A previously reported SNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link>) was included as a tag SNP, using the forced inclusion option. The selected SNPs and SNPs captured by these SNPs are given in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Selected SNP and SNPS captured by these SNPS</title></caption><table frame="hsides" rules="groups"><col width="86" span="1"/><col width="351" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Selected SNP</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>SNPs captured by current SNP</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511990">rs2511990</ext-link>&#x02028;, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2729376">rs2729376</ext-link><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link>&#x02028;, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005511">rs1005511</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511988">rs2511988</ext-link><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs4926">rs4926</ext-link>&#x02028;, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11229066">rs11229066</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11229067">rs11229067</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs3824988">rs3824988</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs3758919">rs3758919</ext-link><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2508443">rs2508443</ext-link>&#x02028;, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: SNP represents single nucleotide polymorphism.</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping of participants</title><p>Peripheral blood sample were anticoagulated with ethylene diamine tetraacetic acid and stored at &#x02212;80&#x000a0;&#x000b0;C before use. Genomic DNA from the blood by Nucleospin &#x000ae;Blood XL kit (Macherey-Nagel GmbH &#x00026; Co., KG D&#x000fc;ren, Germany). The kit contains a silica membrane which can specifically bind DNA. After binding, DNA can be washed out by elute buffer. Genotyping was performed using PCR restriction fragment length polymorphism and direct sequencing.</p><p>The target DNA in <italic>SERPING1</italic> was amplified by PCR using relevant primers. The primers for each SNP were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The primer sequences and restriction enzymes (New England Biolabs, Ipswich, MA) used for each SNP are presented in <xref ref-type="table" rid="t3">Table 3</xref>.</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Primers and restriction enzyme used in this study</title></caption><table frame="hsides" rules="groups"><col width="74" span="1"/><col width="220" span="1"/><col width="38" span="1"/><col width="74" span="1"/><col width="55" span="1"/><col width="103" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>SNP</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Primer sequence</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>AT (&#x000b0;C)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Enzyme</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCR product</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Enzyme products</bold></th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F:TGGGAGCAGGTCTAGGATT<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">60.5<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">BslI (NEB)<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">170 bp<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">29 bp and 141 bp<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">R: CAGGAAGAGCTTTAGTGAG<hr/></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: GGCACAGTCCTCTAAAATAC<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">57.7<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">BbvI (NEB)<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">204 bp<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">102 bp and 102 bp<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">R: CCTGACTATCCCTCATCTT<hr/></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F:TGGCAAAATGTGAGTCGTGTTCCT<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">63<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">BstNI (NEB)<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">293 bp<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">223 bp and 70 bp<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">R: GCCAGTTGGGATCCTCTGGGC<hr/></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">F: GAAGAAGGACTTTCAACTG<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">54.8</td><td rowspan="2" valign="top" align="center" colspan="1">DdeI (NEB)</td><td rowspan="2" valign="top" align="center" colspan="1">102 bp</td><td rowspan="2" valign="top" align="center" colspan="1">21 bp and 81 bp</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">R:TGAGAGGCAAATTCACTC</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NEB represents New England Biolabs, Ipswich, MA; SNP represents single nucleotide polymorphism; AT represents annealing temperature.</p></table-wrap-foot></table-wrap><p>Each PCR was performed in 20&#x000a0;&#x003bc;l of solution containing 10&#x000a0;&#x003bc;l of 2&#x000d7; Power Taq PCR MasterMix (Bioteke Corporation, Beijing, China), 8 pmol of primers, and 50 ng of genomic DNA. The cycling profile was: initial denaturation at 95&#x000a0;&#x000b0;C for 3 min, 33 cycles consisting of 95&#x000a0;&#x000b0;C for 30 s, proper annealing temperature (<xref ref-type="table" rid="t3">Table 3</xref>) for 30 s, 72&#x000a0;&#x000b0;C for 30 s, and a final extension for 10 min at 72&#x000a0;&#x000b0;C.</p><p>The digestion conditions contained 7.25&#x000a0;&#x003bc;l pure water, 1&#x000a0;&#x003bc;l NEB buffer, 0.25&#x000a0;&#x003bc;l enzyme and 1.5&#x000a0;&#x003bc;l PCR product for enzyme BslI, BbvI, and DdeI. The reaction conditions contained 7.15&#x000a0;&#x003bc;l pure water, 1&#x000a0;&#x003bc;l NEB buffer, 0.1&#x000a0;&#x003bc;l BSA, 0.25&#x000a0;&#x003bc;l enzyme and 1.5&#x000a0;&#x003bc;l PCR product for enzyme BstNI. The reaction temperature for enzyme BslI was 55&#x000a0;&#x000b0;C, for enzyme BstNI was 60&#x000a0;&#x000b0;C, and for enzyme BbvI and DdeI was 37&#x000a0;&#x000b0;C. After digestion, all fragments were resolved by electrophoresis on 8% polyacrylamide gel (PAG) at 30 W for 2 h. Subsequently, the PAG was silver stained [<xref ref-type="bibr" rid="r31">31</xref>]. Briefly, the gels were fixed with 1% nitric acid for 5 min and 10% alcohol for 3min. After several changes of water, the gels were incubated in 0.1% silver nitrate for 25 min. Then the gels were developed in 3% sodium carbonate and the reaction was terminated with acetic acid. To confirm the accuracy of the method used, randomly selected subjects (10% of all samples) were analyzed by direct sequencing (Shanghai Sangon Biologic Engineering Technology &#x00026; Service Co. Ltd. Shanghai, China). All the primers used for direct sequencing are available on request.</p></sec><sec><title>Statistical analysis</title><p>Age and gender differences between PCV and control subjects were assessed using the unpaired Student <italic>t</italic>-test and &#x003c7;<sup>2</sup> test, respectively, with SPSS 13.0 for windows software (SPSS Inc., Chicago, IL). Deviations from the Hardy&#x02013;Weinberg equilibrium were tested using the exact test implemented in the <ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/purcell/plink/">software package PLINK</ext-link>, v1.06 [<xref ref-type="bibr" rid="r32">32</xref>]. Genotypes and allele frequencies between cases and controls were evaluated for each SNP using the chi-square test with PLINK. The odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated relative to the minor allele. Haploview software was used to assess LD patterns and haplotype association statistics. Haplotype blocks were determined using the &#x0201c;4-gamete rule&#x0201d; option implemented in Haploview. A p value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 233 subjects were enrolled in this study, comprising 118 unrelated patients with PCV and 115 healthy control individuals (<xref ref-type="table" rid="t1">Table 1</xref>). The mean ages were 65&#x000b1;8.4 years for PCV patients and 69&#x000b1;8.7 years for healthy controls (p&#x0003c;0.001). The percentage of males was 66.1% in the PCV group and 60% in the control group (p=0.335).</p><p>Four SNPs were chosen as tag SNPs. Genotypes were determined successfully by restriction enzyme digestion in all subjects for the four SNPs and confirmed by direct sequencing (<xref ref-type="fig" rid="f2">Figure 2</xref>). None of the four SNPs genotyped in this study showed significant deviation from Hardy&#x02013;Weinberg equilibrium tests in both case and control subjects (all p&#x0003e;0.252).</p><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>PCR restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing for all tag single nucleotide polymorphisms (SNPs). <bold>A</bold>: Restriction analysis for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link> resulted in digestible fragment (C/C), undigestible fragment (T/T), and heterozygote (C/T). <bold>B</bold>: Direct sequencing confirmed the restriction patterns for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link>. <bold>C</bold>: Restriction analysis for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link> resulted in digestible fragment (A/A), undigestible fragment (G/G), and heterozygote (A/G). D. Reverse sequencing confirmed the restriction patterns for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link>. <bold>E</bold>: Restriction analysis for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link> resulted in digestible fragment (C/C), undigestible fragment (T/T), and heterozygote (C/T). <bold>F</bold>: Reverse sequencing confirmed the restriction patterns for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link>. G. Restriction analysis for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link> resulted in digestible fragment (A/A), undigestible fragment (G/G), and heterozygote (A/G). <bold>H</bold>: Reverse sequencing confirmed the restriction patterns for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link>.</p></caption><graphic xlink:href="mv-v16-231-f2"/></fig><p>The minor allele frequencies in each group for all tag SNPs genotyped and the results of the single-SNP association study are summarized in <xref ref-type="table" rid="t4">Table 4</xref>. The results of genotype frequencies for all tag SNPs are shown in <xref ref-type="table" rid="t5">Table 5</xref>. None of the four tag SNPs showed a significant association with PCV (<xref ref-type="table" rid="t4">Table 4</xref> and <xref ref-type="table" rid="t5">Table 5</xref>). The OR for PCV in rs2511989 A/G heterozygotes compared with wild-type G/G homozygotes was 1.08 (95% CI 0.60&#x02013;1.95). A similar comparison of the A/A homozygotes with the wild type yielded an OR of 3.04 (0.31&#x02013;29.77).</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Association test for minor allele frequency between PCV and control subjects</title></caption><table frame="hsides" rules="groups"><col width="68" span="1"/><col width="81" span="1"/><col width="81" span="1"/><col width="66" span="1"/><col width="67" span="1"/><col width="34" span="1"/><col width="64" span="1"/><col width="54" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNP</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Position (bp)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Minor allele</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCV, n</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control, n</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>95% CI</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57119193<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38 (0.161)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33 (0.144)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.69&#x02013;1.90<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5984<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57123798<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">61 (0.259)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52 (0.226)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.78&#x02013;1.83<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.4147<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57130908<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24 (0.102)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (0.096)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.07<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.58&#x02013;1.97<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.8269<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">57134901</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="center" rowspan="1" colspan="1">37 (0.157)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (0.135)</td><td valign="top" align="center" rowspan="1" colspan="1">1.19</td><td valign="top" align="center" rowspan="1" colspan="1">0.71&#x02013;2.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.5013</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CI represents confidence interval; OR represents odds ratio; PCV represents polypoidal choroidal vasculopathy; SNP represents single nucleotide polymorphism.</p></table-wrap-foot></table-wrap><table-wrap id="t5" position="float"><label>Table 5</label><caption><title>Association test for genotype between PCV and control subjects</title></caption><table frame="hsides" rules="groups"><col width="74" span="1"/><col width="66" span="1"/><col width="62" span="1"/><col width="75" span="1"/><col width="34" span="1"/><col width="64" span="1"/><col width="63" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>SNP</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCV, n (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control, n (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>95%CI</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>P value</bold></th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (70.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">84 (73.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.8543<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (27.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29 (25.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.70&#x02013;2.01<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.52<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.25&#x02013;9.32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">63 (53.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69 (60.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5643<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (41.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (34.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.34<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.78&#x02013;2.30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (5.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (5.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.34&#x02013;3.57<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">96 (81.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">95 (82.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.9647<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (16.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18 (15.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.55&#x02013;2.21<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.14&#x02013;7.17<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">84 (71.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">85 (73.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5963<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (26.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29 (25.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.08<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.60&#x02013;1.95<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA</td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">3.04</td><td valign="top" align="center" rowspan="1" colspan="1">0.31&#x02013;29.77</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: SNP represents single nucleotide polymorphism; PCV represents polypoidal choroidal vasculopathy; OR represents odds ratio; 95%CI represents 95% confidence intervals. OR and 95%CI were calculated to estimate risk size as comparison of the homozygote and heterozygote versus wild-type homozygote.</p></table-wrap-foot></table-wrap><p>The pairwise LD structure was constructed with all SNPs genotyped (<xref ref-type="fig" rid="f3">Figure 3</xref>). Three SNPs, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link>, were placed within one haplotype block, and we examined haplotypes based on these three SNPs in the haplotype block. Details of the haplotypes and their frequencies in PCV and control subjects are presented in <xref ref-type="table" rid="t6">Table 6</xref>. No particular haplotype was found to be associated with a risk of PCV.</p><fig id="f3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Linkage disequilibrium structure of serpin peptidase inhibitor, clade G, member 1 (<italic>SERPING1)</italic>. Linkage disequilibrium (LD) was measured using data from all subjects in this study. The haplotype blocks were determined using the &#x0201c;4-gamete rule&#x0201d; option implemented in the Haploview software. Each box provides estimated statistics of the coefficient of determination (r<sup>2</sup>), with darker shades representing stronger LD.</p></caption><graphic xlink:href="mv-v16-231-f3"/></fig><table-wrap id="t6" position="float"><label>Table 6</label><caption><title>Inferred haplotype frequencies and haplotype-based association study</title></caption><table frame="hsides" rules="groups"><col width="73" span="1"/><col width="79" span="1"/><col width="82" span="1"/><col width="36" span="1"/><col width="63" span="1"/><col width="54" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Haplotype*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCV</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>95%CI</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">172.7 (0.732)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174.7 (0.759)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.86<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.57-1.31<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.4911<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">TGT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35.1 (0.149)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30.1 (0.131)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.69-1.96<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5784<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CGC</td><td valign="top" align="center" rowspan="1" colspan="1">22.1 (0.094)</td><td valign="top" align="center" rowspan="1" colspan="1">20.2 (0.088)</td><td valign="top" align="center" rowspan="1" colspan="1">1.07</td><td valign="top" align="center" rowspan="1" colspan="1">0.57-2.02</td><td valign="top" align="center" rowspan="1" colspan="1">0.8198</td></tr></tbody></table><table-wrap-foot><p>All haplotypes with frequency &#x0003e;1% in the combined samples from PCV patients and controls are shown. *Haplotypes were defined by the following three contiguous SNPs: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1005510">rs1005510</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs11603020">rs11603020</ext-link>. Abbreviations: PCV represents polypoidal choroidal vasculopathy; OR represents odds ratio; 95%CI represents 95% confidence intervals.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study we investigated the association of <italic>SERPING1</italic> polymorphisms with PCV in a Chinese Han population. Our study showed that none of the four tag SNPs for <italic>SERPING1</italic> were associated with PCV. The genotyping methods used in this study were different from those in a previous study [<xref ref-type="bibr" rid="r26">26</xref>]. As shown previously [<xref ref-type="bibr" rid="r33">33</xref>,<xref ref-type="bibr" rid="r34">34</xref>], different genotyping technologies could yield inconsistent genotyping results. To validate the results of genotyping, two methods, PCR restriction fragment length polymorphism and direct sequencing, were used in this study.</p><p>PCV shares many similarities with neovascular AMD. However, the histopathological findings remain confusing [<xref ref-type="bibr" rid="r35">35</xref>], and there are distinct clinical differences between PCV and neovascular AMD, including morphologic features and disease progression [<xref ref-type="bibr" rid="r3">3</xref>], as well as response to therapy [<xref ref-type="bibr" rid="r36">36</xref>,<xref ref-type="bibr" rid="r37">37</xref>]. The clinical differences may indicate different genetic characteristics between PCV and neovascular AMD.</p><p>The complement system is a powerful component of innate immunity, which recognizes pathogens and unwanted host material and facilitates their elimination [<xref ref-type="bibr" rid="r38">38</xref>]. Activation of complement leading to membrane attack complex (MAC) formation can be triggered via three known pathways (the classical, lectin, and alternative pathways). The classical pathway is generally initiated by antibody interactions with foreign antigens. The protein encoded by <italic>SERPING1</italic> is an important complement regulator and plays a crucial part in suppressing the activity of C1. Inhibition of C1 prevents activation of C2 and C4, thus the cleavage of C3 into the anaphylatoxin C3a and the major fragment C3b is inhibited. C3b subsequently binds foreign structures and forms a complex with CFB that cleaves C5 (C3bBb, C5 convertase). This complex amplifies the complement response, resulting in the formation of MAC. Variants within several genes that code for proteins involved in the complement system are recognized to either significantly increase the risk of AMD (<italic>CFH</italic> [<xref ref-type="bibr" rid="r9">9</xref>-<xref ref-type="bibr" rid="r11">11</xref>] and <italic>C3</italic> [<xref ref-type="bibr" rid="r23">23</xref>]) or decrease the risk (<italic>SERPING1</italic> [<xref ref-type="bibr" rid="r26">26</xref>], <italic>C2</italic> and <italic>CFB</italic> [<xref ref-type="bibr" rid="r24">24</xref>]).</p><p>Due to the similarities between PCV and AMD, several studies were conducted to test the association between PCV and complement components. Previous studies [<xref ref-type="bibr" rid="r39">39</xref>,<xref ref-type="bibr" rid="r40">40</xref>] showed that several <italic>CFH</italic> variants (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs3753394">rs3753394</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs551397">rs551397</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs800292">rs800292</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2274700">rs2274700</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs1329428">rs1329428</ext-link>) but not the Y402H variant that is the most common variant in western AMD patients, were significantly associated with neovascular AMD in Chinese cohorts. A significant association between PCV and <italic>CFH</italic> variants (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs3753394">rs3753394</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs800292">rs800292</ext-link>) was observed in another Chinese cohort [<xref ref-type="bibr" rid="r18">18</xref>]. Thus it appeared that the alternative pathway might be implicated in the pathogenesis of both PCV and AMD.</p><p>Several studies showed a protective effect on neovascular AMD for <italic>C2</italic> and <italic>BF</italic> [<xref ref-type="bibr" rid="r24">24</xref>,<xref ref-type="bibr" rid="r41">41</xref>]. However, the association was not observed between PCV and <italic>C2</italic> in a Chinese cohort [<xref ref-type="bibr" rid="r18">18</xref>]. Ennis [<xref ref-type="bibr" rid="r26">26</xref>] reported a protective effect on AMD for <italic>SERPING1</italic>; however, no association between PCV and <italic>SERPING1</italic> was observed in this study. Both <italic>C2</italic> and <italic>SERPING1</italic> are crucial regulators of the classic complement pathway. Given the published data and the results of this study, we hypothesized that the classic pathway might play a minor role in the pathogenesis of PCV compared with neovascular AMD. However, further studies containing larger numbers of PCV and neovascular AMD patients should be conducted to test our hypotheses.</p><p>Drusen is abnormal accumulations of extracellular material that forms between the basal surface of the retinal pigmented epithelium and Bruch&#x02019;s membrane. It is a significant risk factor for the development of AMD [<xref ref-type="bibr" rid="r42">42</xref>]. Previous studies showed that several complement components were found in drusen, including C3a and C5b-9 [<xref ref-type="bibr" rid="r43">43</xref>,<xref ref-type="bibr" rid="r44">44</xref>]. The prevalence of large soft drusen in the fellow eyes of unilateral PCV patients was much less than that among AMD patients [<xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r45">45</xref>]. This clinical difference between PCV and AMD can be partly explained by the genetic differences between them.</p><p>Potential limitations of our study should be mentioned. First, the PCV and control groups were not completely age matched. Second, we did not sample enough neovascular AMD patients and no comparison was conducted between PCV and neovascular AMD in this Chinese Han cohort. Third, no mechanistic and functional evaluations were conducted in this study.</p><p>In summary, this study has been conducted to investigate the association of <italic>SERPING1</italic> polymorphisms with PCV. To our knowledge, this issue has not been investigated to date. We found no evidence to support the role of any common <italic>SERPING1</italic> variation, including <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp?term=rs2511989">rs2511989</ext-link>, in the susceptibility to PCV in a Chinese Han population; thus the focus may be shifted to other loci in future PCV-related genetic association studies.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank all the patients and family members for their participation. This study was supported by the National Basic Research Program of China (grant number 2007CB512206). The authors have no financial or conflicting interests to disclose.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Sorenson</surname><given-names>J</given-names></name><name><surname>Spaide</surname><given-names>RF</given-names></name><name><surname>Lipson</surname><given-names>B</given-names></name></person-group><article-title>Idiopathic polypoidal choroidal vasculopathy (IPCV).</article-title><source>Retina</source><year>1990</year><volume>10</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1693009</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Wong</surname><given-names>DW</given-names></name><name><surname>Sforzolini</surname><given-names>BS</given-names></name><name><surname>Goldbaum</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>KC</given-names></name><name><surname>Spaide</surname><given-names>RF</given-names></name><name><surname>Freund</surname><given-names>KB</given-names></name><name><surname>Slakter</surname><given-names>JS</given-names></name><name><surname>Guyer</surname><given-names>DR</given-names></name><name><surname>Sorenson</surname><given-names>JA</given-names></name><name><surname>Fisher</surname><given-names>Y</given-names></name><name><surname>Maberley</surname><given-names>D</given-names></name><name><surname>Orlock</surname><given-names>DA</given-names></name></person-group><article-title>Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.</article-title><source>Arch Ophthalmol</source><year>1999</year><volume>117</volume><fpage>1503</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10565519</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciardella</surname><given-names>AP</given-names></name><name><surname>Donsoff</surname><given-names>IM</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Costa</surname><given-names>DL</given-names></name><name><surname>Yannuzzi</surname><given-names>LA</given-names></name></person-group><article-title>Polypoidal choroidal vasculopathy.</article-title><source>Surv Ophthalmol</source><year>2004</year><volume>49</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14711438</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name></person-group><article-title>Subtype lesions of neovascular age-related macular degeneration in Chinese patients.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2007</year><volume>245</volume><fpage>1441</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17406882</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruko</surname><given-names>I</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Nagayama</surname><given-names>D</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name></person-group><article-title>Clinical characteristics of exudative age-related macular degeneration in Japanese patients.</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17509509</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Nishihara</surname><given-names>H</given-names></name><name><surname>Yamakoshi</surname><given-names>T</given-names></name><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Taki</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Hamajima</surname><given-names>N</given-names></name><name><surname>Terasaki</surname><given-names>H</given-names></name></person-group><article-title>Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>1722</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17400294</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>JP</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><name><surname>Lai</surname><given-names>TY</given-names></name><name><surname>Choy</surname><given-names>KW</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name></person-group><article-title>Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>456</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16490490</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasaki</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Nagasaka</surname><given-names>T</given-names></name></person-group><article-title>Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation.</article-title><source>Br J Ophthalmol</source><year>2002</year><volume>86</volume><fpage>321</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11864892</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Ritter</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Abel</surname><given-names>KJ</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Panhuysen</surname><given-names>C</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name></person-group><article-title>Complement factor H polymorphism and age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>421</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15761121</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Gallins</surname><given-names>P</given-names></name><name><surname>Spencer</surname><given-names>KL</given-names></name><name><surname>Kwan</surname><given-names>SY</given-names></name><name><surname>Noureddine</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Complement factor H variant increases the risk of age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>419</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15761120</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Zeiss</surname><given-names>C</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Tsai</surname><given-names>JY</given-names></name><name><surname>Sackler</surname><given-names>RS</given-names></name><name><surname>Haynes</surname><given-names>C</given-names></name><name><surname>Henning</surname><given-names>AK</given-names></name><name><surname>SanGiovanni</surname><given-names>JP</given-names></name><name><surname>Mane</surname><given-names>SM</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Bracken</surname><given-names>MB</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Barnstable</surname><given-names>C</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name></person-group><article-title>Complement factor H polymorphism in age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>385</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15761122</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Fagerness</surname><given-names>J</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Seddon</surname><given-names>JM</given-names></name></person-group><article-title>Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1055</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16936732</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Atmaca-Sonmez</surname><given-names>P</given-names></name><name><surname>Othman</surname><given-names>M</given-names></name><name><surname>Branham</surname><given-names>KE</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name><name><surname>Wade</surname><given-names>MS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Zareparsi</surname><given-names>S</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name></person-group><article-title>CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1049</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16936733</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Hartman</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Barnstable</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name></person-group><article-title>HTRA1 promoter polymorphism in wet age-related macular degeneration.</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>989</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17053108</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Camp</surname><given-names>NJ</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Gibbs</surname><given-names>D</given-names></name><name><surname>Cameron</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pearson</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chien</surname><given-names>J</given-names></name><name><surname>Dewan</surname><given-names>A</given-names></name><name><surname>Harmon</surname><given-names>J</given-names></name><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Shridhar</surname><given-names>V</given-names></name><name><surname>Zabriskie</surname><given-names>NA</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name><name><surname>Howes</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>992</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17053109</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Loenhardt</surname><given-names>T</given-names></name><name><surname>Janssen</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>Keilhauer</surname><given-names>CN</given-names></name><name><surname>Weber</surname><given-names>BH</given-names></name></person-group><article-title>Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>892</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18511946</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurada</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Mabuchi</surname><given-names>F</given-names></name><name><surname>Imasawa</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>N</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name></person-group><article-title>Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy.</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><fpage>1058</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">18400199</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Vithana</surname><given-names>EN</given-names></name><name><surname>Mathur</surname><given-names>R</given-names></name><name><surname>Yong</surname><given-names>VH</given-names></name><name><surname>Yeo</surname><given-names>IY</given-names></name><name><surname>Thalamuthu</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Koh</surname><given-names>AH</given-names></name><name><surname>Lim</surname><given-names>MC</given-names></name><name><surname>How</surname><given-names>AC</given-names></name><name><surname>Wong</surname><given-names>DW</given-names></name><name><surname>Aung</surname><given-names>T</given-names></name></person-group><article-title>Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>2613</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18515590</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Kuno</surname><given-names>S</given-names></name><name><surname>Negi</surname><given-names>A</given-names></name></person-group><article-title>Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.</article-title><source>Ophthalmology</source><year>2009</year><volume>116</volume><fpage>304</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19187823</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Tsukahara</surname><given-names>Y</given-names></name><name><surname>Negi</surname><given-names>A</given-names></name></person-group><article-title>LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population.</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>608</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17692272</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Yoshimura</surname><given-names>N</given-names></name></person-group><article-title>Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population.</article-title><source>Clin Experiment Ophthalmol</source><year>2008</year><volume>36</volume><fpage>437</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18939352</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Otani</surname><given-names>A</given-names></name><name><surname>Tsujikawa</surname><given-names>A</given-names></name><name><surname>Yamashiro</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Yoshimura</surname><given-names>N</given-names></name></person-group><article-title>ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy.</article-title><source>Am J Ophthalmol</source><year>2009</year><volume>147</volume><fpage>1037</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19268887</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Sepp</surname><given-names>T</given-names></name><name><surname>Matharu</surname><given-names>BK</given-names></name><name><surname>Khan</surname><given-names>JC</given-names></name><name><surname>Thurlby</surname><given-names>DA</given-names></name><name><surname>Shahid</surname><given-names>H</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Armbrecht</surname><given-names>AM</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Redmond</surname><given-names>E</given-names></name><name><surname>Bird</surname><given-names>AC</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name></person-group><article-title>Complement C3 variant and the risk of age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>553</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17634448</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Zernant</surname><given-names>J</given-names></name><name><surname>Hancox</surname><given-names>LS</given-names></name><name><surname>Taiber</surname><given-names>AJ</given-names></name><name><surname>Gehrs</surname><given-names>K</given-names></name><name><surname>Cramer</surname><given-names>K</given-names></name><name><surname>Neel</surname><given-names>J</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Barile</surname><given-names>GR</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name></person-group><article-title>Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>458</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16518403</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>HM</given-names></name><name><surname>Frank</surname><given-names>MM</given-names></name></person-group><article-title>Complement 1 inhibitor is a regulator of the alternative complement pathway.</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>1609</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11733575</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ennis</surname><given-names>S</given-names></name><name><surname>Jomary</surname><given-names>C</given-names></name><name><surname>Mullins</surname><given-names>R</given-names></name><name><surname>Cree</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Macleod</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>E</given-names></name><name><surname>Lotery</surname><given-names>A</given-names></name></person-group><article-title>Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1828</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18842294</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Ryu</surname><given-names>E</given-names></name><name><surname>Tosakulwong</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Edwards</surname><given-names>AO</given-names></name></person-group><article-title>Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects.</article-title><source>Mol Vis</source><year>2009</year><volume>15</volume><fpage>200</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19169411</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Japnese Study Group of Polypoidal Choroidal Vasculopathy</collab></person-group><article-title>Criteria for diagnosis of polypoidal choroidal vasculopathy.</article-title><source>Nippon Ganka Gakkai Zasshi</source><year>2005</year><volume>109</volume><fpage>417</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16050460</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The International HapMap Consortium</collab></person-group><article-title>The International HapMap Project.</article-title><source>Nature</source><year>2003</year><volume>426</volume><fpage>789</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">14685227</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Minoda</surname><given-names>K</given-names></name></person-group><article-title>Detection of congenital color vision defects using heteroduplex-SSCP analysis.</article-title><source>Jpn J Ophthalmol</source><year>1996</year><volume>40</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">8739504</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Bender</surname><given-names>D</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses.</article-title><source>Am J Hum Genet</source><year>2007</year><volume>81</volume><fpage>559</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorentzen</surname><given-names>AR</given-names></name><name><surname>Celius</surname><given-names>EG</given-names></name><name><surname>Ekstrom</surname><given-names>PO</given-names></name><name><surname>Wiencke</surname><given-names>K</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name><name><surname>Myhr</surname><given-names>KM</given-names></name><name><surname>Ling</surname><given-names>V</given-names></name><name><surname>Thorsby</surname><given-names>E</given-names></name><name><surname>Vartdal</surname><given-names>F</given-names></name><name><surname>Spurkland</surname><given-names>A</given-names></name><name><surname>Harbo</surname><given-names>HF</given-names></name></person-group><article-title>Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.</article-title><source>J Neuroimmunol</source><year>2005</year><volume>166</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">16005527</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Makridakis</surname><given-names>N</given-names></name><name><surname>Reichardt</surname><given-names>JKV</given-names></name><name><surname>Ross</surname><given-names>RK</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name></person-group><article-title>No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>2456</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18469342</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yuzawa</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>R</given-names></name></person-group><article-title>Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy.</article-title><source>Jpn J Ophthalmol</source><year>2004</year><volume>48</volume><fpage>249</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15175917</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Seong</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Koh</surname><given-names>HJ</given-names></name><name><surname>Kwon</surname><given-names>OW</given-names></name></person-group><article-title>Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.</article-title><source>Ophthalmologica</source><year>2004</year><volume>218</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">15103216</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>RM</given-names></name><name><surname>Figueira</surname><given-names>J</given-names></name><name><surname>Cachulo</surname><given-names>ML</given-names></name><name><surname>Duarte</surname><given-names>L</given-names></name><name><surname>Faria de Abreu</surname><given-names>JR</given-names></name><name><surname>Cunha-Vaz</surname><given-names>JG</given-names></name></person-group><article-title>Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2005</year><volume>243</volume><fpage>973</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15864616</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>BP</given-names></name></person-group><article-title>The complement system: an overview.</article-title><source>Methods Mol Biol</source><year>2000</year><volume>150</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10857099</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Chong</surname><given-names>KK</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Association of complement factor H polymorphisms with exudative age-related macular degeneration.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>1536</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17167412</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>TK</given-names></name><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>YJ</given-names></name><name><surname>Chong</surname><given-names>KK</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Chiang</surname><given-names>SW</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Multiple gene polymorphisms in the complement factor h gene are associated with exudative age-related macular degeneration in chinese.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>3312</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18421087</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>AJ</given-names></name><name><surname>Islam</surname><given-names>FM</given-names></name><name><surname>Guymer</surname><given-names>RH</given-names></name><name><surname>Baird</surname><given-names>PN</given-names></name></person-group><article-title>Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD).</article-title><source>Invest Ophthalmol Vis Sci</source><year>2009</year><volume>50</volume><fpage>540</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">18806293</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelsalam</surname><given-names>A</given-names></name><name><surname>Del Priore</surname><given-names>L</given-names></name><name><surname>Zarbin</surname><given-names>MA</given-names></name></person-group><article-title>Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression.</article-title><source>Surv Ophthalmol</source><year>1999</year><volume>44</volume><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">10466585</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Leitner</surname><given-names>WP</given-names></name><name><surname>Staples</surname><given-names>MK</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name></person-group><article-title>Complement activation and inflammatory processes in drusen formation and age related macular degeneration.</article-title><source>Exp Eye Res</source><year>2001</year><volume>73</volume><fpage>887</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11846519</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Luthert</surname><given-names>PJ</given-names></name><name><surname>Chong</surname><given-names>NHV</given-names></name><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name><name><surname>Mullins</surname><given-names>RF</given-names></name></person-group><article-title>An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.</article-title><source>Prog Retin Eye Res</source><year>2001</year><volume>20</volume><fpage>705</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11587915</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladas</surname><given-names>ID</given-names></name><name><surname>Rouvas</surname><given-names>AA</given-names></name><name><surname>Moschos</surname><given-names>MM</given-names></name><name><surname>Synodinos</surname><given-names>EE</given-names></name><name><surname>Karagiannis</surname><given-names>DA</given-names></name><name><surname>Koutsandrea</surname><given-names>CN</given-names></name></person-group><article-title>Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population.</article-title><source>Eye</source><year>2004</year><volume>18</volume><fpage>455</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15131673</pub-id></mixed-citation></ref></ref-list></back></article>